Drug . | n . | % . |
---|---|---|
NNRTI | ||
efavirenz | 1643 | 87.6 |
nevirapine | 104 | 5.5 |
rilpivirine | 92 | 5.0 |
etravirine | 37 | 2.0 |
total NNRTI | 1876 | 100 |
PI | ||
lopinavir | 422 | 23.4 |
nelfinavir | 239 | 13.3 |
atazanavir | 642 | 35.6 |
darunavir | 291 | 16.1 |
fosamprenavir | 49 | 2.7 |
saquinavir | 28 | 1.6 |
indinavir | 122 | 6.8 |
amprenavir | 11 | 0.6 |
total PI | 1804 | 100 |
INSTI | ||
raltegravir | 131 | 45.0 |
elvitegravir | 118 | 40.6 |
dolutegravir | 42 | 14.4 |
total INSTI | 291 | 100 |
Drug . | n . | % . |
---|---|---|
NNRTI | ||
efavirenz | 1643 | 87.6 |
nevirapine | 104 | 5.5 |
rilpivirine | 92 | 5.0 |
etravirine | 37 | 2.0 |
total NNRTI | 1876 | 100 |
PI | ||
lopinavir | 422 | 23.4 |
nelfinavir | 239 | 13.3 |
atazanavir | 642 | 35.6 |
darunavir | 291 | 16.1 |
fosamprenavir | 49 | 2.7 |
saquinavir | 28 | 1.6 |
indinavir | 122 | 6.8 |
amprenavir | 11 | 0.6 |
total PI | 1804 | 100 |
INSTI | ||
raltegravir | 131 | 45.0 |
elvitegravir | 118 | 40.6 |
dolutegravir | 42 | 14.4 |
total INSTI | 291 | 100 |
Drug . | n . | % . |
---|---|---|
NNRTI | ||
efavirenz | 1643 | 87.6 |
nevirapine | 104 | 5.5 |
rilpivirine | 92 | 5.0 |
etravirine | 37 | 2.0 |
total NNRTI | 1876 | 100 |
PI | ||
lopinavir | 422 | 23.4 |
nelfinavir | 239 | 13.3 |
atazanavir | 642 | 35.6 |
darunavir | 291 | 16.1 |
fosamprenavir | 49 | 2.7 |
saquinavir | 28 | 1.6 |
indinavir | 122 | 6.8 |
amprenavir | 11 | 0.6 |
total PI | 1804 | 100 |
INSTI | ||
raltegravir | 131 | 45.0 |
elvitegravir | 118 | 40.6 |
dolutegravir | 42 | 14.4 |
total INSTI | 291 | 100 |
Drug . | n . | % . |
---|---|---|
NNRTI | ||
efavirenz | 1643 | 87.6 |
nevirapine | 104 | 5.5 |
rilpivirine | 92 | 5.0 |
etravirine | 37 | 2.0 |
total NNRTI | 1876 | 100 |
PI | ||
lopinavir | 422 | 23.4 |
nelfinavir | 239 | 13.3 |
atazanavir | 642 | 35.6 |
darunavir | 291 | 16.1 |
fosamprenavir | 49 | 2.7 |
saquinavir | 28 | 1.6 |
indinavir | 122 | 6.8 |
amprenavir | 11 | 0.6 |
total PI | 1804 | 100 |
INSTI | ||
raltegravir | 131 | 45.0 |
elvitegravir | 118 | 40.6 |
dolutegravir | 42 | 14.4 |
total INSTI | 291 | 100 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.